- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04471844
Ключевое, рандомизированное, открытое исследование Optune® (поля для лечения опухолей) в сочетании с RT и TMZ для лечения недавно диагностированной глиобластомы (EF-32)
EF-32: ключевое, рандомизированное, открытое исследование Optune® (поля для лечения опухолей, 200 кГц) в сочетании с лучевой терапией и темозоломидом для лечения недавно диагностированной глиобластомы
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
Обзор исследования
Подробное описание
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Innsbruck
-
Innsbruck, Innsbruck, Австрия, 6020
- Innsbruck University Hospital
-
-
Linz
-
Linz, Linz, Австрия, 4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Австрия, 5020
- University Hospital Salzburg
-
-
-
-
-
Liège, Бельгия, B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
-
Essen, Германия, 45147
- University Hospital Essen
-
Freiburg im Breisgau, Германия, 79106
- University Medical Center Freiburg
-
Leipzig, Германия, 04103
- University Hospital Leipzig
-
Munich, Германия, 81675
- Rechts der Isar Hospital
-
Tübingen, Германия, 72076
- University Hospital Tübingen
-
-
-
-
-
Jerusalem, Израиль, 9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa, Haifa District, Израиль, 3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva, Petah Tikva, Израиль, 49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan, Ramat Gan, Израиль, 52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Израиль, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney, Nova Scotia, Канада, B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa, Ontario, Канада
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Канада
- Princess Margaret Cancer Centre
-
Toronto, Ontario, Канада
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Канада, H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke, Quebec, Канада
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
-
Liverpool, Соединенное Королевство, L7 8YA
- Clatterbridge Cancer Centre
-
London, Соединенное Королевство, SE1 9RT
- Guy's Hospital
-
London, Соединенное Королевство, W6 8RF
- Charing Cross Hospital
-
Nottingham, Соединенное Королевство, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston, Соединенное Королевство, PR29HT
- Royal Preston Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Соединенные Штаты, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, Соединенные Штаты, 85054
- Mayo Clinic- Arizona
-
Tucson, Arizona, Соединенные Штаты, 85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville, Arkansas, Соединенные Штаты, 72762
- Highlands Oncology Group
-
-
California
-
Burbank, California, Соединенные Штаты, 91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte, California, Соединенные Штаты, 91010
- City of Hope National Medical Center
-
Fullerton, California, Соединенные Штаты, 92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla, California, Соединенные Штаты, 92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars - Sinai Medical Center
-
Los Angeles, California, Соединенные Штаты, 90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach, California, Соединенные Штаты, 92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange, California, Соединенные Штаты, 92868
- St. Joseph Hospital of Orange
-
Orange, California, Соединенные Штаты, 92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto, California, Соединенные Штаты, 94303
- Stanford University Cancer Institute
-
San Diego, California, Соединенные Штаты, 92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco, California, Соединенные Штаты, 94143
- University of California San Francisco Medical Center
-
Santa Monica, California, Соединенные Штаты, 90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- University of Colorado Cancer Center Anschutz
-
Englewood, Colorado, Соединенные Штаты, 80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford, Connecticut, Соединенные Штаты, 06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton, Florida, Соединенные Штаты, 33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville, Florida, Соединенные Штаты, 32224
- Mayo Clinic
-
Jacksonville, Florida, Соединенные Штаты, 32207
- Baptist Health - Jacksonville
-
Orlando, Florida, Соединенные Штаты, 32804
- AdventHealth
-
Orlando, Florida, Соединенные Штаты, 32806
- Orlando Health UF Health Cancer Center
-
Tampa, Florida, Соединенные Штаты, 33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30342
- Northside Hospital, Inc.
-
Atlanta, Georgia, Соединенные Штаты, 30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta, Georgia, Соединенные Штаты, 30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60612
- Rush University Medical Center
-
Chicago, Illinois, Соединенные Штаты, 60617
- University of Chicago
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka, Kansas, Соединенные Штаты, 66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, Соединенные Штаты, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Соединенные Штаты, 70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans, Louisiana, Соединенные Штаты, 70072
- LSU Health Sciences Center, New Orleans
-
New Orleans, Louisiana, Соединенные Штаты, 70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland, Maine, Соединенные Штаты, 04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02111
- Tufts Medical Center
-
Worcester, Massachusetts, Соединенные Штаты, 01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson, Mississippi, Соединенные Штаты, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Соединенные Штаты, 65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City, Missouri, Соединенные Штаты, 64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, Соединенные Штаты, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, Соединенные Штаты, 08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack, New Jersey, Соединенные Штаты, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City, New Jersey, Соединенные Штаты, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success, New York, Соединенные Штаты, 11042
- Northwell Health System Brain Tumor Center
-
New York, New York, Соединенные Штаты, 10029
- Mount Sinai - Icahn School of Medicine
-
New York, New York, Соединенные Штаты, 10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York, New York, Соединенные Штаты, 10032
- New York Presbyterian - Columbia University
-
Rochester, New York, Соединенные Штаты, 14642
- University of Rochester Medical Center
-
Syracuse, New York, Соединенные Штаты, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Соединенные Штаты, 28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville, North Carolina, Соединенные Штаты, 27834
- Vidant Medical Center
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Соединенные Штаты, 27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, Соединенные Штаты, 43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence, Rhode Island, Соединенные Штаты, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Соединенные Штаты, 29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga, Tennessee, Соединенные Штаты, 37404
- SCRI - Tennessee Oncology
-
Germantown, Tennessee, Соединенные Штаты, 38138
- West Cancer Center - Germantown
-
Nashville, Tennessee, Соединенные Штаты, 37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas, Texas, Соединенные Штаты, 75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth, Texas, Соединенные Штаты, 76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston, Texas, Соединенные Штаты, 77030
- Houston Methodist Hospital
-
Houston, Texas, Соединенные Штаты, 77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple, Texas, Соединенные Штаты, 76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington, Vermont, Соединенные Штаты, 05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98122
- Swedish Health Services
-
Seattle, Washington, Соединенные Штаты, 98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown, West Virginia, Соединенные Штаты, 26506
- West Virginia University Cancer Institute
-
-
-
-
-
Angers, Франция, 49055
- Institut de cancérologie de l'Ouest
-
Bron, Франция, 69677
- Pierre Wertheimer Hospital
-
Marseille, Франция, 13305
- Hôpital la Timone
-
Nice, Франция, 06000
- University Hospital Nice
-
Paris, Франция, 75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain, Франция, 44800
- Institut de cancérologie de l'Ouest
-
Toulouse, Франция, 31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif, Франция, 94805
- Gustave Roussy Institute
-
-
-
-
Brno
-
Brno, Brno, Чехия, 656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen, Pilsen, Чехия, 305 99
- University Hospital Plzeň
-
-
Prague
-
Prague, Prague, Чехия, 150 30
- Na Homolce Hospital
-
-
-
-
-
Lausanne, Швейцария, CH-1011
- Lausanne University Hospital
-
Zurich, Швейцария, 8091
- University Hospital Zurich
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Япония, 920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi, Saitama, Япония, 350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi, Tokyo-To, Япония, 181-8611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo-To, Япония, 162-8666
- Tokyo Women's Medical University Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
Активный компаратор: RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall Survival (OS)
Временное ограничение: 5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression Free Survival (PFS)
Временное ограничение: 5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
Временное ограничение: 5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
Временное ограничение: 5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
Временное ограничение: 5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
Временное ограничение: 5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
Временное ограничение: 5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
Временное ограничение: 5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
Временное ограничение: 5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Общие публикации
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- TRIDENT EF-32
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .